Biotech and Pharma Update: January 2014
Kava Plant May Prevent Cigarette Smoke-induced Lung Cancer *** Conditional Approval for Treatment of T-cell Lymphoma in Dogs *** All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C...
View ArticleFTC Sues to Stop Unlawful Blocking of Generic Androgel
The FTC is seeking a court judgment declaring that the defendants’ conduct violates the FTC Act, ordering the companies to disgorge their ill-gotten gains, and permanently barring them from engaging in...
View ArticleGenetic and Stem Cell Therapies to Treat Cancers
There are certainly some signs for hope. One of them came recently from Princeton University, where graduate students worked on a project which identified a treatment for blocking an enzyme which is...
View ArticlePatent settlement between AbbVie and Amgen delays Humira generic until 2023
On Thursday, September 28th, a judge in the District of Delaware entered an order stipulating dismissal in a patent infringement case brought by North Chicago-based pharmaceutical firm AbbVie...
View ArticleWhen Post-Filing Evidence to Determine Written Description Support Is...
May a court rely on post-priority-date evidence offered to show that a patent lacks written description support even though written description is judged based on the state of the art as of the...
View ArticleLitigants May Not Use a DJ to Obtain Piecemeal Adjudication
The Federal circuit heard the case on AbbVie Inc. v. MedImmune Ltd. AbbVie and MedImmune entered a development and licensing agreement in 1995. The agreement stemmed from a research collaboration...
View ArticleDrug-Patent Abuse and the High Cost of Healthcare: Case of the Double-Half...
Ever since the Supreme Court decided KSR v. Teleflex, it has been appropriate to reject a patent claim because it was obvious to try. If twice the dose intravenously, half as often works, why wouldn’t...
View ArticleThe Abuse of Orange Book Listings by Branded Pharmaceutical Companies
AbbVie’s maneuver worked like clockwork to induce regulatory gridlock, which prevented generic competition and kept the company’s profits high at public expense, for years. Fortunately, the FTC would...
View ArticleChina extends drug patent exclusivity to 25 years
Among members of the news media, patents have been a popular whipping boy when contemplating why Americans pay higher drug prices relative to the rest of the world. Meanwhile, the Chinese national...
View ArticleHouse Committee Targets AbbVie Patent Practices, Urges FTC to Investigate
Yesterday, Representatives Carolyn Maloney (D-NY), Jerrold Nadler (D-NY) and David Cicilline (D-RI) asked Federal Trade Commission (FTC) Acting Chair Rebecca Kelly Slaughter to open a formal inquiry...
View ArticleFederal Trade Commission Urges SCOTUS to Deny AbbVie Petition
On Wednesday, May 19, the response brief of the Federal Trade Commission (FTC) was filed with the U.S. Supreme Court in AbbVie v. FTC. The petition for writ of certiorari filed by AbbVie asks the...
View ArticleSeventh Circuit Throws Out Antitrust Suit Against AbbVie in Welcome Victory...
The U.S. Court of Appeals for the Seventh Circuit agreed with a district court earlier this week that neither a settlement agreement between AbbVie and a number of generic biologics companies, nor the...
View Article
